5444-05-3

Basic information

• Product Name: 3-(acetyloxy)-4,5-dimethoxybenzoic acid
• CAS NO: 5444-05-3
• Molecular Formula: C₁₁H₁₂O₆
• Molecular Weight: 240.2094
• Mol File: 5444-05-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 150-151℃
• Boiling Point: 355.7°C at 760 mmHg
• Flash Point: 135.3°C
• Density: 1.28g/cm³
• Vapor Pressure: 1.12E-05mmHg at 25°C
• Refractive Index: 1.529
• CAS DataBase Reference: 3-(acetyloxy)-4,5-dimethoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(acetyloxy)-4,5-dimethoxybenzoic acid(5444-05-3)
• EPA Substance Registry System: 3-(acetyloxy)-4,5-dimethoxybenzoic acid(5444-05-3)

Safety Data

• Hazardous Substances Data: 5444-05-3(Hazardous Substances Data)

Upstream product

• 83011-43-2 3-hydroxy-4,5-dimethoxybenzoate 
• 121-33-5 vanillin 
• 6948-30-7 5-bromoveratralaldehyde 
• 20731-48-0 3-bromo-4,5-dimethoxybenzoic acid 
• 2973-76-4 5-bromo-4-hydroxy-3-methoxybenzaldehyde 
• 1916-08-1 3-hydroxy-4,5-dimethoxybenzoic acid 
• 108-24-7 acetic anhydride 

Relevant articles and documents

MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS

The present invention relates to macrocyclic diamine derivatives of formula II, including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the macrocyclic diamine derivatives with an adenosine receptor antagonist, for the treatment of cancers.

1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.